Overview
Short anti-inflammatory peptide.
Works on gut conditions like Crohn’s and colitis, plus systemic inflammation.
Injected SubQ.
What It Does
Alpha-MSH C-terminal tripeptide, potent gut and systemic anti-inflammatory via MC1R/MC3R.
Tripeptide (Lys-Pro-Val) from alpha-MSH.
Binds MC1R/MC3R to suppress NF-κB, IL-6, TNF-α, and promote gut barrier integrity.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 5 mg | + 1 mL | 5 mg/mL |
| 10 mg | + 2 mL | 5 mg/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| SubQ (gut) | Daily | 0.5–2 mg | Gut-targeted anti-inflammatory. |
| SubQ (systemic) | Daily | 0.5–1 mg | Systemic. |
| Off | 2–4 weeks | – | Essential break between cycles. Skipping leads to tolerance and diminishing returns. |
4–6 weeks on / 2–4 weeks off. Max: 8 weeks on / 4 weeks off.
Daily, anytime; SubQ.
α-MSH fragment; preclinical only, no human dosing RCT.
Unisex anti-inflammatory (an α-MSH fragment), same protocol for men and women, no cycle effect.
Handling & Stacking
Safety & Patient Education
- Limited human data, use for gut conditions is community-standard but not RCT-supported.
- PCAC RECOMMENDED it for the 503A bulks list, 8–6 (Jul 2026; advisory, non-binding; FDA rulemaking pending).
- Compound-specific: hsCRP baseline + end if used for an inflammatory indication; fecal calprotectin baseline + end if used for gut/IBD; otherwise no routine markers needed., Out of range?
- A still-elevated hsCRP or calprotectin = inflammation isn't controlled yet (reassess dose or duration).
